REMD Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.remdbio.com
Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab
Phase 1
Recruiting
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Biological: Volagidemab
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- REMD Biotherapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06272695
- Locations
- 🇺🇸
Diablo Clinical Research, Walnut Creek, California, United States
🇺🇸Altman Clinical and Translational Research Institute, San Diego, California, United States
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Biological: REMD-477Biological: Placebo Comparator
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- REMD Biotherapeutics, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT03117998
- Locations
- 🇺🇸
AMCR Institute, Escondido, California, United States
🇺🇸Marin Endocrine Care & Research, Greenbrae, California, United States
🇺🇸Altman Clinical and Translational Research Institute, San Diego, California, United States
Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Type 1 Diabetes MellitusDiabetes
- Interventions
- Biological: REMD-477Biological: Placebo Comparator
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- REMD Biotherapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT02715193
Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- DiabetesType 2 Diabetes Mellitus
- Interventions
- Biological: REMD-477
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- REMD Biotherapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT02455011
© Copyright 2025. All Rights Reserved by MedPath